ATE337339T1 - Therapeutische verwendung von smr1 protein und seinen aktiven derivaten - Google Patents

Therapeutische verwendung von smr1 protein und seinen aktiven derivaten

Info

Publication number
ATE337339T1
ATE337339T1 AT98912339T AT98912339T ATE337339T1 AT E337339 T1 ATE337339 T1 AT E337339T1 AT 98912339 T AT98912339 T AT 98912339T AT 98912339 T AT98912339 T AT 98912339T AT E337339 T1 ATE337339 T1 AT E337339T1
Authority
AT
Austria
Prior art keywords
therapeutic
well
molecules
present
preventing
Prior art date
Application number
AT98912339T
Other languages
English (en)
Inventor
Catherine Rougeot
Francois Rougeon
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE337339T1 publication Critical patent/ATE337339T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/854—Glands
AT98912339T 1997-02-20 1998-02-19 Therapeutische verwendung von smr1 protein und seinen aktiven derivaten ATE337339T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/801,405 US6589750B2 (en) 1997-02-20 1997-02-20 Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives

Publications (1)

Publication Number Publication Date
ATE337339T1 true ATE337339T1 (de) 2006-09-15

Family

ID=25181003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912339T ATE337339T1 (de) 1997-02-20 1998-02-19 Therapeutische verwendung von smr1 protein und seinen aktiven derivaten

Country Status (10)

Country Link
US (4) US6589750B2 (de)
EP (2) EP1702929A3 (de)
AT (1) ATE337339T1 (de)
AU (1) AU6721998A (de)
CA (1) CA2281912A1 (de)
DE (1) DE69835680T2 (de)
DK (1) DK1007566T3 (de)
ES (1) ES2271991T3 (de)
PT (1) PT1007566E (de)
WO (1) WO1998037100A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DK1185294T3 (da) * 1999-06-23 2005-08-01 Centre Nat Rech Scient Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser
ATE288763T1 (de) * 2000-12-22 2005-02-15 Pasteur Institut Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden
CA2514507C (en) 2003-01-28 2012-03-20 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1577320T3 (da) * 2004-03-19 2012-10-15 Pasteur Institut Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
DE102004026744A1 (de) * 2004-05-28 2005-12-29 Philipps-Universität Marburg Erfindung betreffend cDNA-Herstellung aus Zellen nach Laser-Mikrodissektion
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009124948A1 (en) 2008-04-07 2009-10-15 Institut Pasteur Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopetidases
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2608050T3 (es) 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN109212006A (zh) * 2018-08-24 2019-01-15 北京艾普希隆生物科技有限公司 一种单细胞琼脂糖凝胶电泳试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374170D1 (en) 1982-05-06 1987-12-03 Massachusetts Inst Technology Production of enterovirus neutralizing antibodies from vp1
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
GB8327966D0 (en) 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
WO1995000848A1 (en) * 1993-06-23 1995-01-05 The Regents Of The University Of California Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DK1185294T3 (da) * 1999-06-23 2005-08-01 Centre Nat Rech Scient Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser
ATE288763T1 (de) * 2000-12-22 2005-02-15 Pasteur Institut Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden

Also Published As

Publication number Publication date
US6589750B2 (en) 2003-07-08
DK1007566T3 (da) 2007-01-02
AU6721998A (en) 1998-09-09
WO1998037100A3 (en) 1999-01-07
EP1007566B1 (de) 2006-08-23
CA2281912A1 (en) 1998-08-27
US7429448B2 (en) 2008-09-30
EP1007566A2 (de) 2000-06-14
DE69835680D1 (de) 2006-10-05
US20020019008A1 (en) 2002-02-14
EP1702929A3 (de) 2007-05-23
US20030195155A1 (en) 2003-10-16
WO1998037100A2 (en) 1998-08-27
US20020198361A1 (en) 2002-12-26
US6818405B2 (en) 2004-11-16
ES2271991T3 (es) 2007-04-16
PT1007566E (pt) 2007-01-31
EP1702929A2 (de) 2006-09-20
DE69835680T2 (de) 2007-08-23
US20040047805A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
ATE337339T1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
AU1922101A (en) Human fgf-21 gene and gene expression products
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
EA200300845A1 (ru) Модифицированные антитела и способы применения
ATE342358T1 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
DE69840909D1 (de) Analoge von kokain
GR3031509T3 (en) Keratinocyte growth factor (KGF) for its use in method of therapeutic treatment for the human or animal body.
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
SI2157192T1 (sl) Sestavki za diagnozo in terapijo bolezni, povezanih z aberantno ekspresijo Futrinov (R-Spondinov)
DE69727691D1 (de) Verwendung von keratinocyten-wachstumsfaktor-2
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie
RU94039629A (ru) Стимулятор роста костномозговых клеток человека
AU7435298A (en) Compositions for enhancing immunosuppressants' pharmaceutical acti vities

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007566

Country of ref document: EP